Back HIV/AIDS

HIV / AIDS

CROI 2015: Antiretroviral Therapy -- Past, Present and Future [VIDEO]

Antiretroviral therapy (ART) has undergone a remarkable evolution from AZT monotherapy in the late 1980s, to effective combination therapy in the mid-1990s, to today's well-tolerated single-tablet regimens. But questions about the optimal time to start treatment remain unanswered and getting ART to everyone who needs it is still a challenge, according to a presentation by David Cooper at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

March 10 Is National Women and Girls HIV/AIDS Awareness Day

Tuesday, March 10, is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), an annual opportunity to call attention to the impact of HIV and AIDS on women and girls worldwide.

alt

CROI 2015: Triple-Drug Combination Superior for Preventing Mother-to-Child HIV Transmission

Implementing the World Health Organization (WHO) recommendation of 3-drug antiretroviral treatment during pregnancy leads to a significantly lower rate of mother-to-child HIV transmission, a 7-country randomized study has shown. The results of the PROMISE study, conducted in sub-Saharan Africa and India, were presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

CROI 2015: Statins May Reduce Risk of Heart Disease in People with HIV

Evidence is mounting that statin therapy can prevent the progression of coronary atherosclerosis (hardening and narrowing of the arteries supplying the heart) in people living with HIV, according to the results of 2 randomized clinical trials reported last week at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

CROI 2015: 3-Drug ART Prevents Vertical HIV Transmission [VIDEO]

Pregnant women treated with a standard 3-drug antiretroviral therapy (ART) regimen were less likely to transmit HIV to their babies that those given only zidovudine (AZT; Retrovir) and nevirapine (Viramune), according to results from the PROMISE study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

 

[Mary Glenn Fowler, CROI, February 24, 2015]

"We had very low transmission rates les than 2% for both strategies, however there was significantly decreased transmission for the triple arms compared to the zidovudine arm," Mary Glenn Fowler from Johns Hopkins School of Medicine said at a CROI press conference. But the triple regimen was associated with an overall increase in moderate but not severe maternal adverse events, as well as a higher risk of moderate adverse pregnancy outcomes such as low birth weight and pre-term delivery.

SEE ALSO: CROI 2015: Triple-Drug Combination Superior for Preventing Mother-to-Child HIV Transmission

3/5/15

Reference

MG Fowler, M Qin, SA Fiscus, et al. PROMISE: Efficacy and Safety of 2 Strategies to Prevent Perinatal HIV Transmission‚Ä®. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 31LB.

CROI 2015: Combining PrEP and ART Could Nearly Eliminate HIV Infection

Giving both pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to heterosexual couples where one partner has HIV (serodiscordant couples) can almost eliminate the chance of infection of the HIV negative partner, a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle has shown.

alt

CROI 2015: Antiretrovirals in the Pipeline: New Tenofovir and HIV Maturation Inhibitor [VIDEO]

Tenofovir alafenamide, a new formulation that works as well as the current formulation but is easier on the kidneys and bones, and BMS-955176, a maturation inhibitor that prevents HIV from producing complete new infectious virus, were among the novel antiretroviral drugs discussed at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle.

alt